CCO Oncology Podcast

Expert Insight on New Data From SGO 2023 Informing Treatment for Endometrial, Cervical, and Ovarian Cancers

Episode Summary

In this podcast episode, listen to David Scott Miller, MD, FACOG, FACS, and Linda Duska, MD, MPH, discuss key data for gynecologic cancers presented at the 2023 SGO Annual Meeting, including practice changing data for endometrial cancers, and for novel combinations in ovarian cancer, and studies exploring sequencing immunotherapy and chemoradiation in cervical cancer.

Episode Notes

In this episode, David Scott Miller, MD, FACOG, FACS, and Linda Duska, MD, MPH, provide expert insights on practice-changing data and other new findings presented at SGO 2023 in endometrial, cervical, and ovarian cancers, including:

• NRG GY018: randomized phase III study evaluating standard of care of carboplatin plus paclitaxel with or without pembrolizumab as frontline treatment for patients with endometrial cancer
• ENGOT-EN6/GOG-3031/RUBY: randomized, placebo-controlled phase III study of dostarlimab plus standard-of-care chemotherapy in primary advanced or recurrent endometrial cancer
• Phase I NRG-GY017 study of priming-dose atezolizumab before or concurrently with chemoradiotherapy in locally advanced high-risk cervical cancer
• Randomized phase II study of chemoradiation plus pembrolizumab immunotherapy in locally advanced cervical cancer
• GOG 3026: phase II trial of letrozole plus ribociclib in women with recurrent low-grade serous ovarian cancer

Presenters:

David Scott Miller, MD, FACOG, FACS
Amy and Vernon E. Faulconer Distinguished Chair in Medical Science
Director and Dallas Foundation Chair in Gynecologic Oncology
Professor of Obstetrics & Gynecology
Fred F. Florence Bioinformation Center
University of Texas Southwestern Medical Center
Medical Director of Gynecologic Oncology Chair, Cancer Committee
Parkland Health & Hospital System
Dallas, Texas

Linda Duska, MD, MPH
Gynecologic Oncologist
Department of OB GYN/Gynecologic Oncology
University of Virginia School of Medicine
Charlottesville, Virginia

Content supported by educational grants from AstraZeneca, GlaxoSmithKline, Merck Sharp & Dohme Corp, Novocure Inc., and Seagen Inc.

Link to full program: bit.ly/424E3Uq